Diversity of pharmacogenomic variants affecting warfarin metabolism in Sri Lankans.
暂无分享,去创建一个
[1] S. Kimmel,et al. Genetic Factors Influencing Warfarin Dose in Black‐African Patients: A Systematic Review and Meta‐Analysis , 2019, Clinical pharmacology and therapeutics.
[2] A. Kocael,et al. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey , 2019, Molecular Biology Reports.
[3] S. Wong,et al. Genotype‐guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta‐analysis of randomized controlled trials , 2018, British journal of clinical pharmacology.
[4] P. C. Santos,et al. Genotype-guided warfarin therapy: current status. , 2018, Pharmacogenomics.
[5] J. Indrakumar. New oral anticoagulants in clinical practice – time to replace warfarin? , 2017 .
[6] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update , 2017, Clinical pharmacology and therapeutics.
[7] G. Wang,et al. Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials , 2015, PloS one.
[8] Y. Wang,et al. Effect of gene polymorphims on the warfarin treatment at initial stage , 2015, The Pharmacogenomics Journal.
[9] M. Pirmohamed,et al. A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction , 2014, PloS one.
[10] William K Redekop,et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. , 2014, British journal of clinical pharmacology.
[11] D. Shewade,et al. Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population , 2013, Indian journal of human genetics.
[12] D. Hu,et al. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. , 2012, Thrombosis research.
[13] R. Desnick,et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. , 2010, Pharmacogenomics.
[14] M. Rieder,et al. CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant , 2009, Molecular Pharmacology.
[15] Russ B. Altman,et al. PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single‐drug pharmacogenetics , 2008, Human mutation.
[16] A. Wittkowsky. Warfarin and Other Coumarin Derivatives: Pharmacokinetics, Pharmacodynamics, and Drug Interactions , 2003, Seminars in vascular medicine.
[17] H. Echizen,et al. Pharmacogenetics of Warfarin Elimination and its Clinical Implications , 2001, Clinical pharmacokinetics.
[18] S. Ham,et al. MECHANISM of action of vitamin K. , 1956, Nutrition reviews.